Answers are grounded in this paper and cite their sources.
Uncovers cuproptosis-related biomarkers and drug candidates in type A aortic dissection, highlighting potential therapeutic targets.
Background Stanford type A aortic dissection (AAD) is a life-threatening vascular emergency characterized by high mortality and a lack of targeted pharmacological interventions. Cuproptosis, a recently defined copper-dependent regulated cell death modality, has been implicated in various cardiovascular pathologies, yet its specific molecular role in the development of AAD remains largely unexplored. Methods We performed an integrated bioinformatics analysis using three independent GEO datasets (GSE107844, GSE147026, and GSE190635) to identify cuproptosis-related differentially expressed genes (DEGs) in AAD tissues. A panel of diagnostic biomarkers was selected using three machine learning algorithms: Random Forest, Support Vector Machine-Recursive Feature Elimination (SVM-RFE), and Boruta. The expression of identified hub genes was validated in clinical patient samples and a BAPN/Ang II-induced AAD mouse model via qRT-PCR and histological staining. Potential therapeutic agents were identified through the Drug-Gene Interaction Database (DGIdb) and validated using molecular docking. Results A total of 31 cuproptosis-related DEGs were identified. Six key genes were identified via PPI and machine learning algorithms. The differential expression patterns of these genes were validated by qRT-PCR in both AAD mouse model and clinical tissues. Subsequently, clinical correlation analysis revealed that MT1G and NLRP3 expression correlated significantly with inflammatory (white blood cell count, IL-6) and coagulation markers (D-dimer). The area under the receiver operating characteristic curve (AUC) for MT1G and NLRP3 was comparable to that of D-dimer, indicating their potential value as biomarkers. Via screening using the DGIdb and validation by molecular docking, compounds such as Buthionine sulfoximine (targeting MT1G), dapansutrile (targeting NLRP3), and ARP100 (targeting DBT) demonstrated favorable binding affinity to their targets. Conclusion Our findings suggest that cuproptosis-related genes may play a role in AAD pathogenesis and provide candidate biomarkers and therapeutic leads for further investigation.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: